Vaxart (OTCMKTS:VXRT) and Gyre Therapeutics (NASDAQ:GYRE) Head-To-Head Comparison

Gyre Therapeutics (NASDAQ:GYRE) and Vaxart (OTCMKTS:VXRT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Valuation and Earnings

This table compares Gyre Therapeutics and Vaxart”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59 million	5.96	$5.03 million	($0.09)	-69.22
Vaxart	$237.26 million	0.60	$16.33 million	$0.15	3.93

Vaxart has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Gyre Therapeutics and Vaxart, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1	1	2	0	2.25
Vaxart	0	1	0	0	2.00

Gyre Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 172.87%. Given Gyre Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Vaxart.

Profitability

This table compares Gyre Therapeutics and Vaxart’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Vaxart	14.51%	61.43%	20.07%

Institutional and Insider Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 18.0% of Vaxart shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 2.8% of Vaxart shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Gyre Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.